Trade

with

Dynavax Technologies Corp
(NASDAQ: DVAX)
AdChoices
1.62
+0.09
+5.88%
After Hours :
1.62
0.00
0.00%

Open

1.52

Previous Close

1.53

Volume (Avg)

5.00M (1.61M)

Day's Range

1.52-1.63

52Wk Range

1.10-2.14

Market Cap.

402.21M

Dividend Rate ( Yield )

-

Beta

2.56

Shares Outstanding

262.88M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 11.25M

    • Net Income

    • -66.72M

    • Market Cap.

    • 402.21M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -615.40

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.56

    • Forward P/E

    • -

    • Price/Sales

    • 29.33

    • Price/Book Value

    • 2.67

    • Price/Cash flow

    • -6.16

      • EBITDA

      • -65.39M

      • Return on Capital %

      • -54.65

      • Return on Equity %

      • -64.43

      • Return on Assets %

      • -54.65

      • Book Value/Share

      • 0.57

      • Shares Outstanding

      • 262.88M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -10.10

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -21.23

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -546.66

            • 39.38

            • Net Profit Margin

            • -615.40

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -385.70

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 7.96

              • 2.92

              • Quick Ratio

              • 7.71

              • 2.35

              • Interest Coverage

              • 1,142.49

              • 38.02

              • Leverage Ratio

              • 1.15

              • 2.21

              • Book Value/Share

              • 0.57

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -4.71

                • 243.90

                • P/E Ratio 5-Year High

                • -16.64

                • 634.30

                • P/E Ratio 5-Year Low

                • -3.05

                • 124.82

                • Price/Sales Ratio

                • 28.99

                • 9.29

                • Price/Book Value

                • 2.63

                • 8.39

                • Price/Cash Flow Ratio

                • -6.16

                • 49.75

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -64.43

                        (-136.40)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -54.65

                        (-53.50)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -64.49

                        (-94.80)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.09

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -66.49M
                      Operating Margin
                      -590.95
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -6.16
                      Ownership

                      Institutional Ownership

                      65.43%

                      Top 10 Institutions

                      46.50%

                      Mutual Fund Ownership

                      38.58%

                      Float

                      84.65%

                      5% / Insider Ownership

                      0.73%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • AST Federated Aggressive Growth

                      •  

                        17,993,000

                      • 0.00

                      • 6.84

                      • Federated Kaufmann Small Cap Fund

                      •  

                        16,122,000

                      • -3.46

                      • 6.13

                      • Polar Capital Healthcare Opps

                      •  

                        10,483,854

                      • 0.00

                      • 3.99

                      • Vanguard Total Stock Mkt Idx

                      •  

                        5,726,102

                      • 28.93

                      • 2.18

                      • Franklin Biotechnology Discovery

                      •  

                        5,418,400

                      • 137.36

                      • 2.06

                      • Harbor Small Cap Growth Fund

                      •  

                        5,278,298

                      • 29.49

                      • 2.01

                      • Putnam Voyager Fund

                      •  

                        5,170,700

                      • 11.11

                      • 1.97

                      • SPDR® S&P Biotech ETF

                      •  

                        4,747,246

                      • -9.83

                      • 1.86

                      • iShares Russell 2000 (AU)

                      •  

                        3,958,417

                      • -1.81

                      • 1.55

                      • Vanguard Extended Market Index Fund

                      •  

                        3,242,077

                      • 0.23

                      • 1.23

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Federated Global Inv Mgmt Corp

                      •  

                        34,115,000

                      • +89.48%

                      • 12.98

                      • RA Capital Management, LLC

                      •  

                        14,036,590

                      • -21.51%

                      • 5.34

                      • Westfield Capital Management Company, LP

                      •  

                        13,668,111

                      • -0.15%

                      • 5.20

                      • Polar Capital LLP

                      •  

                        10,946,861

                      • +1.85%

                      • 4.16

                      • State Street Corp

                      •  

                        10,146,462

                      • -26.03%

                      • 3.86

                      • Vanguard Group, Inc.

                      •  

                        9,101,496

                      • -0.36%

                      • 3.46

                      • BlackRock Fund Advisors

                      •  

                        8,258,043

                      • +2.96%

                      • 3.14

                      • Franklin Advisers, Inc.

                      •  

                        7,879,100

                      • 0.00%

                      • 3.00

                      • Broadfin Capital, LLC

                      •  

                        7,660,100

                      • 0.00%

                      • 2.91

                      • Putnam Investment Management,LLC

                      •  

                        6,449,368

                      • +11.58%

                      • 2.45

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Slow Growth

                      Style

                      Small Core

                      Dynavax Technologies Corp was incorporated in California in August 1996 under the name Double Helix Corporation, and it changed its name to Dynavax Technologies Corporation in September 1996. The Company reincorporated in Delaware in...more 2000. The Company is a clinical-stage biopharmaceutical company. It discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company’s product candidate is HEPLISAVTM, a Phase 3 investigational adult hepatitis B vaccine. Its pipeline of product candidates includes: HEPLISAV, its autoimmune program partnered with GlaxoSmithKline, and its therapy for asthma partnered with AstraZeneca AB. Its product candidates are based on the use of immunostimulatory and immunoregulatory sequences. HEPLISAV is an investigational adult hepatitis...more B vaccine. In Phase 3 trials, HEPLISAV demonstrated higher and earlier protection with fewer doses than currently licensed vaccines. The Company has worldwide commercial rights to HEPLISAV. HEPLISAV combines its first generation 1018 ISS with hepatitis B surface antigen manufactured in its facility in Düsseldorf, Germany. The Company competes with pharmaceutical companies, biotechnology companies, academic institutions and research organizations, in developing therapies to prevent or treat infectious diseases and inflammatory and autoimmune diseases. Any product candidate it develops is subject to extensive regulation by federal, state and local governmental authorities in the United States, including the FDA and foreign regulatory agencies.lessless

                      Key People

                      Eddie Gray

                      CEO/Director

                      Dr. Arnold L. Oronsky,PhD

                      Chairman of the Board/Director

                      Michael S. Ostrach

                      CFO/General Counsel/Other Executive Officer/Secretary/Vice President

                      David L. Johnson,C.P.A.

                      Vice President/Chief Accounting Officer

                      Mr. Robert Janssen

                      Chief Medical Officer/Vice President, Divisional

                      • Dynavax Technologies Corp

                      • 2929 Seventh Street

                      • Berkeley, CA 94710-2753

                      • USA.Map

                      • Phone: +1 510 848-5100

                      • Fax: +1 510 848-1327

                      • dynavax.com

                      Incorporated

                      1996

                      Employees

                      151

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: